Showing promise in the landscape of obesity therapy, retatrutide is a unique approach. Different from many available medications, retatrutide works as a twin agonist, simultaneously engaging both glucagon-like peptide-1 (GLP-1) and glucose-sensitive insulinotropic substance (GIP) sensors. The concurrent engagement promotes various beneficial effect